Approval Year
| Substance Class |
Nucleic Acid
Created
by
admin
on
Edited
Sat Dec 16 17:36:04 UTC 2023
by
admin
on
Sat Dec 16 17:36:04 UTC 2023
|
| Nucleic Acid Type | mRNA VACCINE |
| Nucleic Acid Subtype | TRANSGENE |
| Sequence Origin | VIRAL |
| Sequence Type | COMPLETE |
| Record UNII |
JV8KBX6XZG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
JV8KBX6XZG
Created by
admin on Sat Dec 16 17:36:04 UTC 2023 , Edited by admin on Sat Dec 16 17:36:04 UTC 2023
|
PRIMARY | |||
|
300000019017
Created by
admin on Sat Dec 16 17:36:04 UTC 2023 , Edited by admin on Sat Dec 16 17:36:04 UTC 2023
|
PRIMARY | |||
|
11888
Created by
admin on Sat Dec 16 17:36:04 UTC 2023 , Edited by admin on Sat Dec 16 17:36:04 UTC 2023
|
PRIMARY | |||
|
C173052
Created by
admin on Sat Dec 16 17:36:04 UTC 2023 , Edited by admin on Sat Dec 16 17:36:04 UTC 2023
|
PRIMARY | |||
|
2417899-75-1
Created by
admin on Sat Dec 16 17:36:04 UTC 2023 , Edited by admin on Sat Dec 16 17:36:04 UTC 2023
|
PRIMARY |
| Sugar | Site Range | Site Count |
|---|---|---|
| D-Ribose (RNA) | 1_2-1_1262 | 1261 / 1262 |
| 2'-O-Methyl-Ribose | 1_1 | 1 / 1262 |
| Linkage | Site Range | Site Count |
|---|---|---|
| Phosphate | 1_2-1_1262 | 1261 / 1261 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->VACCINE ANTIGEN |
|
||
|
EXPRESSED PROTEIN->VECTOR |
|
||
|
EXPRESSED PROTEIN->VECTOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Designed to produce neutralizing antibody to the SARS-CoV-2 S glycoprotein. The intention is that such antibodies would protect against SARS-CoV-2 infection and its resulting disease, COVID-19
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| NUCLEOSIDE_SUBSTITUTION | RESIDUE_SPECIFIC | N1-METHYLPSEUDOURIDINE | 09RAD4M6WF | |||
| NUCLEOTIDE SUBSTITUTION | [1_1] | 5'-TERMINUS | m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP | VNP8CZY34V |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| S1S2 RBD codon optimized sequence | NUCLEIC ACID FEATURE |
|
|
|||
| nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues | NUCLEIC ACID FEATURE |
|
|
|||
| Partial sequence of T4 fibritin (foldon), used as a trimerization domain | NUCLEIC ACID FEATURE |
|
|
|||
| S glycoprotein signal peptide | NUCLEIC ACID FEATURE |
|
|
|||
| 5'-UTR sequence of the human alpha-globin mRNA with an optimized ʻKozak sequenceʼ | NUCLEIC ACID FEATURE |
|
|
|||
| GS linker sequence | NUCLEIC ACID FEATURE |
|
|
|||
| 3´-UTR comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA, to confer RNA stability and high total protein expression | NUCLEIC ACID FEATURE |
|
|
|||